AE Wealth Management’s Amicus Therapeutics FOLD Stock Holding History

AE Wealth Management’s Portfolio FOLD Stock Details FOLD Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2020 Q2	–	Sell	-38,249	Closed	-$353K	–	1287
2020 Q1	$353K	Buy	+38,249	New	+$364K	0.01%	826

Other funds holding FOLD

Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return

Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

ACA

Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

AE Wealth Management's FOLD Position: Q2 2020 in Review

AE Wealth Management sold out of Amicus Therapeutics (FOLD) in Q2 2020, closing a stake of 38,249 shares — an estimated $353K sold.

AE Wealth Management first reported a position in FOLD in Q1 2020 and held it in 1 quarter. The position peaked at $353K in Q1 2020. 226 funds tracked by Wall St. Rank hold FOLD as of Q2 2020.

AE Wealth Management reported no remaining Amicus Therapeutics position as of Q2 2020 after selling out during the quarter.
AE Wealth Management sold 38,249 Amicus Therapeutics shares in Q2 2020, an estimated $353K.
AE Wealth Management first reported a position in Amicus Therapeutics in Q1 2020 and held it in 1 quarter.
AE Wealth Management's Amicus Therapeutics position peaked at $353K in Q1 2020.
226 funds tracked by Wall St. Rank held Amicus Therapeutics as of Q2 2020.

Based on AE Wealth Management's 13F filing for Q2 2020, filed 5 Aug 2020.